{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007059","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.709911+00:00","generated_at":"2026-06-02T17:48:27.174229+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Quanterix Q1 revenue $32.1M (+12.7%); net loss $10.1M; FDA breakthrough for P-tau217 test","bullets":["Revenue $32.1M (+12.7% YoY); net loss $10.1M (increase of $4.0M YoY).","GAAP gross margin 61.2% (up 170 bps); non-GAAP gross margin 54.5% (up 140 bps).","FY 2024 guidance unchanged: revenue $139-$144M, GAAP gross margin 57-61%, non-GAAP 51-55%.","Director Brian J. Blaser resigned board eff. May 3, 2024 to become CEO of QuidelOrtho; no disagreement.","Simoa P-tau217 blood test granted FDA Breakthrough Device; Lilly launched CertuitAD test on SP-X platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007059","json":"https://secwatch.observer/filing/0001558370-24-007059.json","markdown":"https://secwatch.observer/filing/0001558370-24-007059.md","text":"https://secwatch.observer/filing/0001558370-24-007059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/0001558370-24-007059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/tmb-20240502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:48:27.174229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7573a8fdf5fe77e8b3349d5c110d1481b40849c4","claim":"Quanterix Corp reported first quarter ended March 31, 2024 results: revenue $32.1 million. Guidance reaffirmed.","evidence_excerpt":"to study and enable the early detection of neuro-pathologies such as Multiple Sclerosis, Parkinson’s, and Alzheimer’s disease.” First Quarter Financial Highlights ● Revenue of $32.1 million, an increase of 12.7% compared to $28.5 million in the prior year period. ● GAAP gross margin of 61.2%, an increase of approximately 170 basis points compared to the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/0001558370-24-007059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$32.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7f66c65903","claim":"Brian J. Blaser resigned as Director at Quanterix Corp.","evidence_excerpt":"On May 2, 2024, Brian J. Blaser notified Quanterix of his resignation from its Board of Directors, effective as of May 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/0001558370-24-007059-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}